Vertex Pharmaceuticals/ US92532F1003 /
| 2024-04-24 9:59:59 PM | Chg. -5.05 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 400.66USD | -1.24% | 25,838 Turnover: 10.41 mill. |
-Bid Size: - | -Ask Size: - | 103.52 bill.USD | - | 28.52 |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 14.05 USD | 8.33% |
| EPS Diluted: | 13.89 USD | 8.35% |
| Revenues per Share: | 38.21 USD | 9.99% |
| Book Value per Share: | 68.06 USD | 25.77% |
| Cash Flow per Share: | 13.69 USD | -14.75% |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 9,869.20 USD | 10.51% |
| Net Income: | 3,619.60 USD | 8.96% |
| Operating Cash Flow: | 3,537.30 USD | - |
| Cash and Cash Equivalents: | 10,369.10 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 28.52 | 28.96 |
| P/S Ratio: | 10.49 | 10.65 |
| P/BV ratio: | 5.89 | 5.98 |
| P/CF Ratio: | 29.27 | 29.71 |
| PEG: | 3.43 | 3.48 |
| Earnings Yield: | 3.51% | 3.45% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 103.52 bill. USD | 105.1 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 258.31 mill. | |
Profitability
| Gross Profit Margin: | 87.21% |
| EBIT Margin: | 38.83% |
| Net Profit Margin: | 36.68% |
| Return on Equity: | 20.59% |
| Return on Assets: | 15.92% |
Financial Strength
| Liquidity I / Cash Ratio: | 292.30% |
| Liquidity II / Quick Ratio: | 336.37% |
| Liquidity III / Current Ratio: | 398.72% |
| Debt / Equity Ratio: | 29.29% |
| Dynam. Debt / Equity Ratio: | 145.59% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
